For all up-to-date congress details please visit the Congress Website: www.ecnp2021.dk
Tentative Program – update on 14 May 2021
12th European Congress of Neuropathology
31 May – 3 June 2021
Tentative Program – with presentation times & time for Q&A indicated
Times are in Central European Summer Time
(CEST, Copenhagen)
| Monday, 31 May 2021 | |
09:00-18:30 – Exhibit Hall and ePoster viewing open |
|
| 12:00-13:00 – Quick Pitch poster sessions (mini oral poster presentations). See presentation overview | |
| 12:00 | Quick Pitch session 1: Gliomas Quick Pitch session 2: Tumors Quick Pitch session 3: Neurodegenerative diseases Quick Pitch session 4: Neuroinflammatory diseases |
13:00 -13:15 – Welcome |
|
| 13:00 | Bjarne Winther Kristensen, Congress President and President of SNS, Copenhagen, Denmark Martin Lammens, President of Euro-CNS, Antwerpen, Belgium |
13:15-14:00 – Plenary Lecture 1 |
|
| 13:15 | Chair: Bjarne Winther Kristensen, Copenhagen, Denmark (3 min) Brain tumor diagnosis in transition – from single parameter analyses to multiomics Andreas von Deimling, Heidelberg, Germany |
14:00-15:30 – Symposium 1: Cerebrovascular diseases |
|
| Chairs: Raj Kalaria, Newcastle, United Kingdom and Kate Lykke Lambertsen, Odense, Denmark (5 min) | |
| 14:05 | S1.1 Post-stroke inflammation – target or tool for therapy (18+5)
Kate Lykke Lambertsen, Odense, Denmark |
| 14:28 | S1.2 White matter in familial small vessel diseases: CADASIL (18+5)
Anne Joutel, Paris, France |
| 14:51 | S1.3 White matter disease – small vessel pathology and more (18+5)
Elisabet Englund, Lund, Sweden |
| 15:13 | S1.4 (P207) Regional proteomic mapping of the human vanishing white matter brain (5+3)
Jodie Man, Utrecht, the Netherlands |
| 15:22 | S1.5 (P210) Volume and cell number of the hippocampus in depression, schizophrenia, and suicide subjects (5+3)
Karl-Anton Dorph-Petersen, Århus/ Randers, Denmark |
14:00-15:30 – Symposium 2: Genetics of neurodegeneration |
|
| Chairs: Irina Alafuzoff, Uppsala, Sweden, and Colin Smith, Edinburgh, Scotland | |
| 14:05 | S2.1 Clues to the aetiology of neurodegenerative diseases from genomic analysis (18+5)
John Hardy, London, United Kingdom |
| 14:28 | S2.2 Pathology of genetic and sporadic Parkinson’s disease (18+5)
Steve Gentleman, London, United Kingdom |
| 14:51 | S2.3 Genetics of ALS/MND – from genes to translational approaches (18+5)
Pamela Shaw, Shefffield, United Kingdom |
| 15:14 | Panel Discussion (15 ) |
14:00-15:30 – Symposium 3. CNS tumor precision oncology – what is important in the neuropathological setting? |
|
| Chairs: Werner Paulus, Münster, Germany and Christine Haberler, Vienna, Austria (5 min) | |
| 14:05 | S3.1 The laboratory setup needed for CNS tumor precision oncology (15+5)
Felix Sahm, Heidelberg, Germany |
| 14:25 | S3.2. Experience and results from a precision oncology phase I unit (15+5)
Ulrik Lassen, Copenhagen, Denmark |
| 14:45 | S3.3 Molecular diagnostics of brain tumors – current practice and the next frontiers (15+5)
Sebastian Brandner, London, United Kingdom |
| 15:05 | S3.4 (P129) Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma (5+3)
Christian Mirian, Copenhagen/Geneva, Denmark/Switzerland |
| 15:13 | S3.5 (P123) Diffuse midline glioma, H3 K27M-mutant (DMG,H3) with BRAF V600E mutation Presentation of two cases treated with BRAF V600 inhibitors (5+3)
Mónica Mezmezian, Buenos Aires, Argentina |
| 15:21 | S3.6 (P194) Nanocarrier using protoporfirin IX-loaded albumin nanoemulsion for image-guided glioblastoma therapies (5+3)
Luciano Neder, Ribeirao Preto, Brazil (oral presentation withdrawn) |
| 15:30-15:45 – Break. Please visit the Exhibition Hall and ePosters | |
15:45-17:15 – Workshop 1. Primary Tauopathies |
|
| Chairs: Gabor Kovacs, Toronto, Canada and Dennis Dickson, Jacksonville, Florida, USA | |
| 15:50 | W1.1 Overview of tau pathologies: interactive slide session using scanned slides (20+5)
Gabor Kovacs, Toronto, Canada |
| 16:15 | W1.2 Tau pathology related to brain trauma (20+5)
Colin Smith, Edinburgh, Scotland |
| 16:40 | W1.3 (P023) Deconvolving the individual contributions of comorbid tau neuropathologies using deep learning (5+3)
Anthony Vega, Dallas, Texas, USA |
| 16:48 | W1.4 (P019) Aggregates of RNA binding proteins and ER chaperones linked to exosomes in granulovacuolar degeneration of the Alzheimer’s disease brain (5+3)
Alfred Yamoah, Aachen, Germany |
| 16:56 | W1.5 (P018) Tau related changes in post mortem retina in Alzheimer’s disease and other tauopathies (5+3)
Jeroen Hoozemans, Amsterdam, the Netherlands |
| 17:04 | Panel Discussion (11) |
15:45-17:15 – Workshop 2. Muscle biopsy and molecular biology: a successful cooperation |
|
| Chairs: Lammens, Antwerpen, Belgium and Werner Stenzel, Berlin, Germany (4 min) | |
| 15:49 | W2.1 Interactive case discussions (8+5)
Eleonora Aronica, Amsterdam, the Netherlands |
| 16:02 | W2.2 Interactive case discussions (8+5)
Joachim Weis, Aachen, Germany |
| 16:15 | W2.3 Differential diagnosis of vacuolar myopathies in the NGS era (8+5)
Joachim Weis, Aachen, Germany |
| 16:26 | W2.4 Interactive case discussions (8+5)
Willem de Ridder, Antwerp, Belgium |
| 16:41 | W2.5 Interactive case discussions (8+5)
Wilfred den Dunnen, Groningen, the Netherlands |
| 16:54 | W2.6 Interactive case discussions (8+5)
Werner Stenzel, Berlin, Germany |
| 17:07 | W2.7 (P206) Automated large-scale scanning transmission electron microscopy of myopathies with structural abnormalities (5+3)
Carsten Dittmayer, Berlin, Germany |
15:45-17:15 – Workshop 3. Pituitary and sellar lesions |
|
| Chairs: Olivera Casar-Borota, Uppsala, Sweden and Henning Boldt, Odense, Denmark (5 min) | |
| 15:50 | W3.1 The 2017 WHO classification of pituitary neuroendocrine neoplasms. What have we learnt? (14+3)
Olivera Casar-Borota, Uppsala, Sweden |
| 16:07 | W3.2 Morphology meets genomics and epigenomics: should we move towards an integrated tissue diagnosis of PitNETs? (14+3)
Olaf Ansorge, Oxford, United Kingdom |
| 16:24 | W3.3 Molecular pathways and targets in pituitary tumors (14+3)
Marily Theodoropoulou, Munich, Germany |
| 16:41 | W3.4 Pituitary lesions from an endocrinologist’s perspective (14+3)
Marianne Andersen, Odense, Denmark |
| 16:58 | W3.5 Interactive slide-based case presentations (14+3)
Olaf Ansorge, Oxford, United Kingdom |
17:15-17:30 – Break. Please visit the Exhibition Hall and ePosters |
|
17:30-18:15 – Plenary Lecture 2 |
|
| Chair: Paul Ince, Sheffield, United Kingdom (3 min)
Lessons learned from brain banking for neurodegenerative diseases Dennis Dickson, Jacksonville, Florida, USA |
|
| Tuesday, 1 June 2021 | |
09:00-18:30 – Exhibit Hall and ePoster viewing open |
|
| 12:00-13:00 – Quick Pitch poster sessions (mini oral poster presentations). See presentation overview | |
| 12:00 | Quick Pitch session 5: Gliomas Quick Pitch session 6: Tumors I Quick Pitch session 7: Tumors II Quick Pitch session 8: Neuromuscular and storage disorders Quick Pitch session 9: Other topics |
13:00-13:45 – Plenary Lecture 3 |
|
| Chair: Eleonora Aronica, Amsterdam, the Netherlands (3 min) Brain somatic mutations in focal cortical dysplasias Stéphanie Baulac, Paris, France |
|
13:45-14:00 Break. Please visit the Exhibition Hall and ePosters |
|
14:00-15:30 – Symposium 4. The 2021 WHO CNS tumor classification: The Fifth! |
|
| Chairs: Pieter Wesseling, Amsterdam/Utrecht, the Netherlands and Guido Reifenberger, Düsseldorf, Germany | |
| 14:05 | S4.1 From cIMPACT-NOW to WHO 2021 classification of CNS tumors (16+4)
Pieter Wesseling, Amsterdam/Utrecht, the Netherlands |
| 14:25 | S4.2 The WHO 2021 classification of diffuse gliomas (adult & pediatric) (16+4)
Guido Reifenberger, Düsseldorf, Germany |
| 14:45 | S4.3 The WHO 2021 classification of circumscribed gliomas and glioneuronal tumors (16+4)
Dominique Figarella-Branger, Marseille, France |
| 15:05 | S4.4 Panel Discussion(25) |
14:00-15:30 – Symposium 5. Mechanisms of brain inflammation |
|
| Chairs: Hans Lassmann, Vienna, Austria, and Trevor Owens, Odense, Denmark | |
| 14:05 | S5.1 Pathways of drainage of interstitial and cerebrospinal fluids from the brain. Significance for neurological diseases (20+3)
Roxana Carare, Southampton, United Kingdom |
| 14:28 | S5.2 Immune cell interaction with the blood-brain barrier in the pathogenesis of inflammation (20+3) Britta Engelhardt, Bern, Switzerland |
| 14:51 | S5.3 Pathology of different human inflammatory CNS diseases – an expanding spectrum (20+3)
Hans Lassmann, Vienna, Austria |
| 15:14 | S5.4 Panel discussion (15 min) |
14:00-15:30 – Symposium 6. Immuno-oncology |
|
| 14:00 | Chairs: Anna Berghof, Vienna, Austria and Bjarne Kristensen, Odense, Denmark |
| 14:05 | S6.1 The inflammatory microenvironment as a therapeutic target in glioma (16+4)
Anna Berghof, Vienna, Austria |
| 14:25 | S6.2 Genetic changes and T-cell infiltration in gliomas (16+4)
Pim French, Amsterdam, the Netherlands |
| 14:45 | S6.3 Understanding and targeting the microenvironment in IDH-mutant gliomas (16+4)
Lukas Bunse, Mannheim, Germany |
| 15:05 | S6.4 (P111) Single-cell analysis of tumor-associated microglia and macrophages from human glioblastoma (5+3)
Rikke Sick Andersen, Odense, Denmark |
| 15:13 | S6.5 (P115) Deconvolution of immunotherapy-treated glioblastoma identifies cellular heterogeneity and plasticity at the single-cell level (5+3)
Josephine Deleuran Hendriksen, Copenhagen, Denmark |
| 15:21 | S6.6 (P135) Defects of mismatch repair proteins in pediatric high-grade gliomas (5+3)
Christine Haberler, Vienna, Austria |
15:30-15:45 – NanoString Lecture (I) |
|
| 15:30 | Regional and sub-regional neuroinflammatory differences in the brain of sporadic Creutzfeldt-Jakob disease patients Aušrinė Areškevičiūtė, Copenhagen, Denmark |
| 15:30-15:45 – Break. Please visit the Exhibition Hall and ePosters | |
15:45-17:15 – Workshop 4. Slide seminar on human prion diseases: Histotyping and identification of atypical phenotypes |
|
| 15:45 | Chairs, speakers: Ellen Gelpi, Vienna, Austria, and Piero Parchi, Bologna, Italy |
| 15:50 | W4.1 Interactive histotyping of CJD subtypes including genetic and atypical forms (85 minutes total) |
15:45-17:15 – Workshop 5. Case discussions of CNS tumors with multi-layered information |
|
| 15:45 | Chairs: Felix Sahm, Heidelberg, Germany, and David Capper, Berlin, Germany |
| 15:50 | W5.1. Practical NGS evaluation (20+8)
Felix Sahm, Heidelberg, Germany |
| 16:18 | W5.2. Practical DNA methylation evaluation (20+8)
David Capper, Berlin, Germany |
| 16:46 | W5.3. Interactive case discussions (28)
Felix Sahm and David Capper |
15:45-17:15 – Workshop 6. Developmental neuropathology: Recent advances and future challenges |
|
| 15:45 | Chairs: Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark |
| 15:50 | W6.1 The value of postmortem examination in neurodevelopmental diseases (15+5)
Homa Adle-Biassette, Paris, France |
| 16:10 | W6.2. Interneurons in cerebral cortical developmental disorders (15+5)
Jeffrey Golden, Boston, USA |
| 16:30 | W6.3 Neuropathology of focal cortical dysplasias: 2021 update (15+5)
Ingmar Blümcke, Erlangen, Germany |
| 16:50 | W6.4 Panel Discussion (25) |
17:15-17:30 – Break. Please visit the Exhibition Hall and ePosters |
|
17:30-18:30 Free Communications I-II-III (see FC overview) |
|
| Free Communications Session I: CNS Tumors (1 of 2) Free Communications Session II: Neurodegenerative and prion diseases (1 of 2) Free Communications Session III: Other topics (1 of 2) |
|
| Wednesday, 2 June 2021 | |
09:00-18:30 – Exhibit Hall and ePoster viewing open |
|
| 12:00-13:00 – Quick Pitch poster sessions (mini oral poster presentations). See presentation overview | |
| 12:00 | Quick Pitch session 10: Gliomas Quick Pitch session 11: Tumors Quick Pitch session 12: Neuroinflammatory diseases Quick Pitch session 13: Neurodevelopmental diseases and epilepsia Quick Pitch session 14: Other topics |
13:00-13:45 – Plenary Lecture 4 |
|
| 13:00 | Chair: David Scheie, Copenhagen, Denmark (3 min) The invasive behavior of glioma cells in the CNS and their biological characteristics Rolf Bjerkvig, Bergen, Norway |
| 13:45-14:00 – Break. Please visit the Exhibition Hall and ePosters | |
14:00-15:30 – Symposium 7. TDP-43 proteinopathies |
|
| 14:00 | Chairs: Manuela Neumann, Tübingen, Germany, and Olaf Ansorge, Oxford, United Kingdom (5) |
| 14:05 | S7.1 Neuropathology of FTLD-TDP (25+5)
Ian Mackenzie, Vancouver, Canada |
| 14:35 | S7.2 Cellular and system vulnerability in ALS (25+5)
Olaf Ansorge, Oxford, United Kingdom |
| 15:05 | S7.3 (P009) Cognitive decline in amyotrophic lateral sclerosis: neuropathological substrate and genetic determinants (5+3)
Sergi Borrego-Écija, Barcelona, Spain |
| 15:13 | S7.4 (P011) Neuroanatomy of FTD: whole-brain correlations between symptoms and pathologies (5+3)
Marta Scarioni, Amsterdam, the Netherlands |
| 15:21 | S7.5 (P033) Defining and diagnosing neurodegenerative movement disorders through integrated analysis of genetics and neuropathology (MD-GAP) (5+3)
Lesley Wu, London, United Kingdom |
14:00-15:30 – Symposium 8. Myositis – clinical, morphological and differential diagnostic highlights |
|
| 14:00 | Chairs: Werner Stenzel, Berlin, Germany, and Anne Schänzer, Giessen, Germany |
| 14:05 | S8.1 Clinical diagnostic aspects in myositis (18+5)
Olivier Benveniste, Parijs, France |
| 14:28 | S8.2 Morphological diagnostic aspects in myositis (18+5)
Werner Stenzel, Berlin, Germany |
| 14:51 | S8.3 Differential diagnostic aspects in myositis (18+5)
Benedikt Schoser, München, Germany |
| 15:14 | S8.4 (P199) NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients (5+3)
Josephine Radke, Berlin, Germany |
14:00-15:30 – Symposium 9. White matter and oligodendrocyte pathology: new insights in neurodevelopmental diseases and epilepsy |
|
| 14:00 | Chairs: Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark (5 min) |
| 14:05 | S9.1 White matter pathology in vanishing white matter: the role of astroglial pathology (16+4)
Marianna Bugiani, Amsterdam, the Netherlands |
| 14:25 | S9.2 Myelin loss and oligodendrocyte pathology in tuberous sclerosis and other mTORopathies (16+4)
Angelika Muehlebner, Amsterdam, the Netherlands |
| 14:45 | S9.3 White matter in temporal lobe epilepsy: clinico-pathological correlates (16+4)
Maria Thom, London, United Kingdom |
| 15:05 | S9.4 (P081) Mimicking white matter pathology in a 3D-nanofiber cell culture system derived from children with drug-resistant epilepsies (5+3)
Victoria-Elisabeth Gruber, Vienna, Austria |
| 15:13 | S9.5 (P082) DNA methylation-based classification of malformations of cortical development (5+3)
Ingmar Blümcke, Erlangen, Germany |
| 15:21 | S9.6 (P080) The antiseizure and antiepileptogenic effect of matrix metalloproteinase inhibitor IPR-179 and its potential mechanisms of action (5+3)
Diede W. Broekaart, Amsterdam, the Netherlands |
| 15:30-15:45 – Break. Please visit the Exhibition Hall and ePosters | |
15:30-15:45 – NanoString Lecture (II) |
|
| 15:30 | Understanding neuropathological disorders using GeoMx® Digital Spatial Profiler Christoph Koenig, Berlin, Germany |
15:45-17:15 – Workshop 7. Assessment of the contributions of mixed pathologies in the ageing brain |
|
| 15:45 | Chairs: Colin Smith, Edinburgh, Scotland, and Irina Alafuzoff, Uppsala, Sweden |
| 15:50 | W7.1 Mixed pathology in the aged demented (20+5)
Johannes Attems, Newcastle, United Kingdom |
| 16:15 | W7.2 Amygdala, a hotspot of pathology in the aged (20+5)
Irina Alafuzoff, Uppsala, Sweden |
| 16:40 | W7.3 (P037) Unique changes in gene activity in the ventral midbrain precedes dopaminergic degeneration in Parkinson’s disease mouse models (5+3)
Pierre Garcia, Dudelange/Esch-sur-Alzette, Luxembourg |
| 16:48 | W7.4 (P021) Subregional severity of proteinopathies in the hippocampus of late onset Alzheimer’s disease and dementia with Lewy bodies patients (5+3)
Sonja Fixemer, Dudelange/ Belval, Luxembourg |
| 16:56 | W7.5 (P026) Limbic-predominant age-related TDP-43 encephalopathy (LATE) in a cohort of patients with dementia: evidence of an early phase of hippocampal sclerosis (5+3)
Alicia Uceda Heras, Madrid, Spain |
| 17:04 | W7.6 (P022) Diabetes is associated with vascular dementia, not Alzheimer’s disease or Lewy body dementia (5+3) Keivan Javanshiri, Lund, Sweden |
15:45-17:15 – Workshop 8. Progress in the pathological diagnosis of pediatric and adult CNS tumors |
|
| 15:45 | Chairs: Pietsch, Bonn, Germany, and Dominique Figarella-Branger, Marseille, France |
| 15:50 | W8.1. Molecular pathology of epilepsy-related low-grade lesions (15+5)
Tom Jacques, London, United Kingdom |
| 16:10 | W8.2 Modern diagnostics of ependymal tumors (15+5)
Dominique Figarella-Branger, Marseille, France |
| 16:30 | W8.3 Differential diagnostics of primitive “embryonal” tumors (15+5)
Torsten Pietsch, Bonn, Germany |
| 16:50 | W8.4. (P118) EpiDiP.org: an open access epigenomics diagnostic resource (5+3)
Juergen Hench, Basel, Switzerland |
| 16:58 | W8.5 (P102) Establishment of Droplet Digital™ PCR (ddPCR™) for rapid molecular diagnostics of brain tumors (5+3)
Guido Reifenberger, Düsseldorf/Heidelberg, Germany |
| 17:06 | W8.6 (P127) Identification of two main subgroups among posterior pituitary tumors associated with histology, MAPK/PI3K mutations, epigenetic regulator mutations, CNV and outcome (5+3)
Simone Schmid, Berlin, Germany |
15:45-17:15 – Workshop 9. B cells in inflammatory demyelinating diseases |
|
| 15:45 | Chairs: Hans Lassmann, Vienna, Austria, and Trevor Owens, Odense, Denmark |
| 15:50 | W9.1 B-cell inflammation in MS (14+3)
Marvin van Luijn, Rotterdam, the Netherlands |
| 16:07 | W9.2 Roles of B-cells in MS and potential consequences for therapy (14+3)
Amit Bar-Or, Philadelphia, USA |
| 16:24 | W9.3 Antibody mediated autoimmune diseases of the nervous system (14+3)
Romana Höftberger, Vienna, Austria |
| 16:41 | W9.4 MOG encephalomyelitis and NMOSD – insights from animal models (14+3)
Trevor Owens, Odense, Denmark |
| 16:58 | W9.5 CD20+ T cells – a T cell disguised as a B cell (14+3)
Marina von Essen, Copenhagen, Denmark |
17:15-17:30 – Break. Please visit the Exhibition Hall and ePosters |
|
17:30-18:30 – Free Communications IV-V-VI (see FC overview) |
|
| Free Communication session IV: CNS tumors (2 of 2)
Free Communication session V: Neurodegenerative and prion diseases (2 of 2) Free Communication session VI: Other topics (2 of 2)|
|
|
| Thursday, 3 June | |
09:00-18:30 – Exhibit Hall and ePoster viewing open |
|
| 11:30-13:00 – ISN Business Meeting (For ISN Council & Executive Committee only, upon invitation) | |
| 12:00-13:00 – Quick Pitch poster sessions (mini oral poster presentations). See presentation overview | |
| 12:00 | Quick Pitch session 15: Gliomas Quick Pitch session 16: Tumors Quick Pitch session 17: Neuroinflammatory diseases Quick Pitch session 18: Neurodegenerative diseases and leukoencephalopathies |
13:00-13:45 – Plenary Lecture 5 |
|
| Chair: Joachim Weis, Aachen, Germany (3 min) Polyglucosan storage in muscle and brain – disease entities and pathogenesis Berge Minassian, Dallas, USA |
|
| 13:45-14:00 – Break. Please visit the Exhibition Hall and ePosters | |
14:00-15:30 Symposium 10. Neuropathology training, courses and examination (EFN) in Europe |
|
| 14:00 | Chairs: Tibor Hortobagyi, Debrecen/Szeged, Hungary and Wilfred den Dunnen, Groningen, the Netherlands |
| 14:05 | Round-table discussion, with lecturers and participants of Euro-CNS courses, examiners and candidates of EFN examinations. The symposium will cover neuropathology training across Europe – the current situation and challenges of the future |
14:00-15:30 – Symposium 11. Intratumoral heterogeneity |
|
| 14:00 | Chairs: Rolf Bjerkvig, Bergen, Norway, and Hrvoje Miletic, Bergen, Norway |
| 14:05 | S11.1 Longitudinal molecular trajectories of diffuse glioma in adults (14+3)
Roel Verhaak, Farmington, Connecticut, USA |
| 14:22 | S11.2 Epigenomic contribution to glioblastoma heterogeneity (14+3)
Adelheid Woehrer, Vienna, Austria |
| 14:39 | S11.3 Role of intrinsic tumor plasticity and microenvironment in creating intratumoral heterogeneity in glioblastoma (14+3)
Anna Golebiewska, Luxembourg, Luxembourg |
| 14:56 | S11.4 Brain tumor invasion into the CNS – mechanisms of action (14+3)
Rolf Bjerkvig, Bergen, Norway |
| 15:13 | S11.5 (P095) Subependymoma of the posterior fossa may progress to ependymoma: Role of TERT mutation, loss of chromosome 6 and methylome alterations (5+3)
Christian Thomas, Münster, Germany |
| 15:21 | S11.6 (P173) Targeted gene expression, TERT mutation and loss of H3K27me3 in WHO grade III meningiomas across recurrences (5+3)
Andrea Maier, Copenhagen, Denmark |
14:00-15:30 – Symposium 12. Dynamic aspects of amyloid-β |
|
| Chairs: James Nicoll, Southampton, United Kingdom, and Zane Jaunmuktane, London, United Kingdom | |
| 14:05 | S12.1 The relationship between spreading and maturation of amyloid-b pathology in AD (15+5)
Dietmar Thal, Leuven, Belgium |
| 14:25 | S12.2 Evidence for the person-to-person transmissibility of amyloid-β. (15+5)
Zane Jaunmuktane, London, United Kingdom |
| 14:45 | S12.3 Removal of amyloid-β from the brain by immunotherapy (15+5)
James Nicoll, Southampton, United Kingdom |
| 15:05 | S12.4 (P017) Alzheimer’s disease neuropathological change and loss of neuropil and matrix in idiopathic normal pressure hydrocephalus, a model of Alzheimer’s disease (5+3)
Sylwia Libard, Uppsala, Sweden |
| 15:13 | S12.5 (P020) The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease (5+3)
Baayla Boon, Amsterdam, the Netherlands |
| 15:21 | S12.6 (P024) Systemic infection exacerbates cerebral hypoperfusion and blood-brain-barrier breakdown in Alzheimer’s disease and vascular dementia (5+3)
Daniel Asby, Bristol, United Kingdom |
15:30- 15:45 – Break. Please visit the Exhibition Hall and ePosters |
|
15:45-17:15 – Symposium 13. COVID-19 and neuropathology |
|
| 15:45 | Chairs: Safa Al-Sarraj, London, United Kingdom, and Markus Glatzel, Hamburg, Germany |
| 15:50 | S13.1 Brain pathology of COVID-19 (20+3)
Markus Glatzel, Hamburg, Germany |
| 16:13 | S13.2 COVID-19 encephalitis; the pathological evidence (20+3)
Safa Al-Sarraj, London, United Kingdom |
| 16:36 | S13.3 (P234) Olfactory transmucosal SARS-CoV-2 invasion as port of central nervous system entry in COVID-19 (7+3)
Jenny Meinhardt, Berlin, Germany |
| 16:46 | S13.4 (P231) Post-infectious myopathy related to COVID-19 (7+3)
Leila Chimelli, Rio de Janeiro, Brazil |
| 16:45 | Panel discussion (19) The Symposium is supported by the International Society of Neuropathology (ISN) |
17:15-17:30 – Break. Please visit the Exhibition Hall and ePosters |
|
17:30-18:15 – Plenary Lecture 6 |
|
| Chair: Eva Løbner Lund, Copenhagen, Denmark (3 min) Deciphering phenotypic variability and transmission properties of human prion diseases Piero Parchi, Bologna, Italy |
|
18:15-18:30 – Best ePoster Prizes and Closure |
|